Advertisement
Screener

Venrock Adviser, LLC Historic Quarter Change: USA Other Stocks, Sold Out

Venrock Adviser, LLC historic quarter change: USA Other Stocks, Sold out

In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 10 quarters from 2023-12-31 to 2026-06-30, Venrock Adviser, LLC opened 3 positions, added to 1, reduced 2 and sold out of 8.

  • Q2 2025: Stock MERSANA THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 3,574,325.
  • Q2 2025: Stock GLYCOMIMETICS INC; Country of operation United States; Class COM; Shares before 3,000,000.
  • Q3 2024: Stock ARCA BIOPHARMA INC; Country of operation United States; Class COM; Shares before 866,375.
  • Q2 2024: Stock LYRA THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 2,576,093.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1615982), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2020-03-31.

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q2 2025MERSANA THERAPEUTICS INC
CUSIP 59045L106
United StatesCOM3,574,3250-3,574,325$1,230,283$0-$1,230,2832025-08-14
Q2 2025GLYCOMIMETICS INC
CUSIP 38000Q102
United StatesCOM3,000,0000-3,000,000$630,000$0-$630,0002025-08-14
Q3 2024ARCA BIOPHARMA INC
CUSIP 00211Y506
United StatesCOM866,3750-866,375$3,318,216$0-$3,318,2162024-11-14
Q2 2024LYRA THERAPEUTICS INC
CUSIP 55234L105
United StatesCOM2,576,0930-2,576,093$16,023,298$0-$16,023,2982024-08-14
Q2 2024ACELYRIN INC
CUSIP 00445A100
United StatesCOM937,1130-937,113$6,325,513$0-$6,325,5132024-08-14
Q1 2024RAYZEBIO INC
CUSIP 75525N107
United StatesCOM4,030,4710-4,030,471$250,574,382$0-$250,574,3822024-05-15
Q1 2024AMBRX BIOPHARMA INC
CUSIP 641871108
COM2,070,0000-2,070,000$29,476,800$0-$29,476,8002024-05-15
Q1 2024ADVERUM BIOTECHNOLOGIES INC
CUSIP 00773U108
COM5,147,5470-5,147,547$3,875,073$0-$3,875,0732024-05-15

Similar Firms

Firm NameCountry13F ValueHoldings
Westwood Global Investments, LLCUnited States$2.683B20
Turtle Creek Asset Management Inc.Canada$2.673B39
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLCUnited States$2.668B468
PEREGRINE CAPITAL MANAGEMENT LLCUnited States$2.696B290
Welch Group, LLCUnited States$2.662B310
TEXAS PERMANENT SCHOOL FUND CORPUnited States$2.697B11
Henshaw Capital LLCUnited States$2.697B160
CAPITAL INTERNATIONAL LTD /CA/United States$2.698B146
Gladstone Institutional Advisory LLCUnited States$2.699B829
Pallas Capital Advisors LLCUnited States$2.658B862